It's a good question, not sure we have a good answer. Probably the elapsed time has not been long enough to form a good view on how Remestemcel-L is influencing ongoing sequelae.
Some people are going to gradually going to get better without it, others may be permanently injured, and maybe data will emerge that Remestemcel-L treated patients fare better in this regard...
Again in my view the best way forwards is a Phase 4 followup.
I am very concerned that lung fibrosis in particular will become refractory within weeks / a month and difficult to treat~
Overwhelming efficacy - the stats required, page-212
-
- There are more pages in this discussion • 365 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | $1.03 | 97.0¢ | $2.815M | 2.838M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 151781 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 80522 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |